RARE

Ultragenyx Pharmaceutical Inc

Jul 16 • 04:00PM ET

27.31

Dollar change +0.11
Percentage change 0.40	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI VB VXF VBK XBI IWP IBB SCHA VHT IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.88	Insider Own	6.52%	Shs Outstand	93.74M	Perf Week	-34.10%
Market Cap	2.58B	Forward P/E	-	EPS next Y	-3.62	Insider Trans	-2.60%	Shs Float	88.38M	Perf Month	-27.15%
Enterprise Value	2.98B	PEG	-	EPS next Q	-1.30	Inst Own	96.30%	Short Float	7.72%	Perf Quarter	-21.79%
Income	-549.58M	P/S	4.37	EPS this Y	16.06%	Inst Trans	2.59%	Short Ratio	4.69	Perf Half Y	-36.72%
Sales	590.69M	P/B	17.75	EPS next Y	31.37%	ROA	-41.97%	Short Interest	6.82M	Perf YTD	-35.08%
Book/sh	1.54	P/C	5.13	EPS next 5Y	46.75%	ROE	-386.33%	52W High	60.37 -54.76%	Perf Year	-39.50%
Cash/sh	5.32	P/FCF	-	EPS past 3/5Y	2.09% 2.45%	ROIC	-56.89%	52W Low	26.85 1.71%	Perf 3Y	-58.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	16.82% 40.12%	Gross Margin	79.08%	Volatility	8.09% 5.09%	Perf 5Y	-68.95%
Dividend TTM	-	EV/Sales	5.04	EPS Y/Y TTM	26.72%	Oper. Margin	-86.94%	ATR (14)	2.24	Perf 10Y	-72.42%
Dividend Ex-Date	-	Quick Ratio	2.24	Sales Y/Y TTM	33.46%	Profit Margin	-93.04%	RSI (14)	27.59	Recom	1.21
Dividend Gr. 3/5Y	- -	Current Ratio	2.40	EPS Q/Q	22.52%	SMA20	-23.39%	Beta	0.27	Target Price	84.84
Payout	-	Debt/Eq	6.17	Sales Q/Q	27.99%	SMA50	-23.96%	Rel Volume	2.09	Prev Close	27.20
Employees	1294	LT Debt/Eq	5.70	Earnings	May 06 AMC	SMA200	-35.38%	Avg Volume	1.45M	Price	27.31
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.74% -3.15%	Trades		Volume	3,042,865	Change	0.40%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144

Show Previous Ratings

Today 09:38AM	William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
07:00AM	New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public (PR Newswire)
Jul-15-25 08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks) -6.94%
05:46AM	Health Canada extends Evkeeza approval for children with HoFH (Pharmaceutical Technology)
Jul-14-25 04:24PM	Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection (Investor's Business Daily)
08:00AM	Loading…
08:00AM	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
07:53AM	FDA rejects Ultragenyx gene therapy over manufacturing concerns (BioPharma Dive)
07:34AM	Ultragenyx receives complete response letter for UX111 BLA (Pharmaceutical Technology)
Jul-13-25 03:12PM	Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light (Insider Monkey)
Jul-11-25 04:30PM	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
07:51AM	Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (BioPharma Dive)
Jul-10-25 04:17PM	Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease (Investor's Business Daily) -25.11%
10:37AM	Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update (Barrons.com)
10:17AM	RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End (Zacks)
09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
07:52AM	Loading…
07:52AM	Kellogg shares soar on buyout talk, and other early market movers (MarketWatch)
Jul-09-25 04:05PM	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis (GlobeNewswire) +5.12%
12:55AM	Ultragenyx's GTX-102 Receives FDA Breakthrough Therapy Designation for Angelman Syndrome (Insider Monkey)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
Jun-27-25 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome (GlobeNewswire)
Jun-20-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-25 05:00PM	Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-20-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.19%
May-14-25 04:30PM	Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report (GlobeNewswire)
May-08-25 10:25AM	Ultragenyx price target lowered to $100 from $140 at Truist (TipRanks) +7.66%
May-07-25 05:00PM	Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference (GlobeNewswire)
12:15PM	Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
10:45AM	Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
03:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
11:32PM	Loading…
May-06-25 11:32PM	Ultragenyx projects $640M-$670M revenue for 2025 with strong product growth (Seeking Alpha) -9.80%
11:31PM	Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
Apr-30-25 05:00PM	Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-25 10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-25 10:01AM	Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-22-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-16-25 09:49AM	Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline (Seeking Alpha)
Apr-13-25 08:50PM	Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks)
Mar-29-25 04:20PM	Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-19-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-25 09:16AM	Ultragenyx price target lowered to $115 from $140 at Piper Sandler (TipRanks)
Feb-24-25 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
Feb-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-25 08:00AM	Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-14-25 09:48AM	Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-13-25 04:19PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-25 04:30PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update (GlobeNewswire)
08:21AM	Ultragenyx announces new data on UX111 AV gene therapy (TipRanks)
Feb-05-25 08:00AM	Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS (GlobeNewswire)
Jan-17-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:14AM	Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential (Insider Monkey)
Jan-15-25 02:05PM	Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside (Benzinga)
Jan-12-25 11:00AM	Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones (GlobeNewswire)
Jan-06-25 04:30PM	Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:07AM	Ultragenyxs Evkeeza secures EU approval for young children with rare cholesterol disorder (Pharmaceutical Technology)
02:00AM	European Commission (EC) Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:00AM	NHS England Rolls Out Evkeeza (evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) (GlobeNewswire)
Dec-19-24 04:05PM	Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome (GlobeNewswire)
08:00AM	Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Nov-26-24 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-24 10:30AM	Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit (GlobeNewswire)
Nov-06-24 02:27AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... (GuruFocus.com)
Nov-05-24 04:11PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Nov-01-24 09:16AM	What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? (Insider Monkey)
Oct-29-24 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Oct-18-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-24 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Oct-03-24 04:30PM	Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Sep-26-24 08:00AM	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting (GlobeNewswire)
Sep-18-24 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:30PM	Ultragenyx to Participate in Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.62%
Aug-06-24 10:45AM	3 Genomics Stocks That May Transform Personalized Medicine (InvestorPlace)
Aug-02-24 08:15AM	Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD Global Investments LP (Business Wire) +14.31%
07:44AM	Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up (Zacks)
Aug-01-24 04:17PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Jul-25-24 04:05PM	Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-24 08:00AM	Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium (GlobeNewswire)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily)
Jul-19-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-18-24 09:03AM	Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans (Zacks)
Jul-17-24 04:05PM	Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program (GlobeNewswire)
Jun-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-13-24 08:49PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.44%
10:15AM	Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug (Zacks)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '25	Sale	39.24	520	20,405	71,530	May 05 07:18 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 21 '25	Sale	35.11	242	8,497	71,680	May 05 07:18 PM
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM
KAKKIS EMIL D	President & CEO	Dec 30 '24	Sale	42.23	11,727	495,231	2,183,985	Dec 31 02:05 PM
KAKKIS EMIL D	Officer	Dec 30 '24	Proposed Sale	42.23	11,727	495,264		Dec 30 04:32 PM
KAKKIS EMIL D	President & CEO	Dec 10 '24	Sale	50.00	8,273	413,650	2,195,712	Dec 11 06:44 PM
KAKKIS EMIL D	Officer	Dec 10 '24	Proposed Sale	50.00	8,273	413,650		Dec 10 04:12 PM
Horn Howard	Chief Financial Officer	Oct 10 '24	Sale	52.76	7,465	393,853	92,301	Oct 11 04:48 PM
KAKKIS EMIL D	President & CEO	Sep 03 '24	Sale	55.85	20,000	1,117,000	2,223,985	Sep 05 11:53 AM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 03 '24	Sale	56.19	91	5,113	41,551	Sep 05 11:50 AM
KAKKIS EMIL D	Officer	Sep 03 '24	Proposed Sale	55.85	20,000	1,117,096		Sep 03 04:40 PM
KAKKIS EMIL D	President & CEO	Aug 06 '24	Sale	50.17	20,000	1,003,400	2,243,985	Aug 07 02:48 PM
KAKKIS EMIL D	Officer	Aug 06 '24	Proposed Sale	50.17	20,000	1,003,418		Aug 06 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your FINVIZ experience